Angiogenesis is closely associated with wound healing, inflammation, rheumatoid arthritis, diabetic retinopathy, macular degeneration, and tumor growth. During the growth process of organisms, angiogenesis is an important component of new tissue formation. In adulthood, apart from periodic events tightly regulated in specific organs, nearly every normal tissue lacks substantial physiological angiogenesis due to the balance between pro-angiogenic and anti-angiogenic endogenous factors. When the balance toward pro-angiogenesis is disrupted, microvascular endothelial cells (ECs) can adopt an angiogenic phenotype, initiating angiogenic responses that can be either eliminated or accelerated. Traditional in vivo angiogenesis experimental methods involved in research include corneal micropocket, mesenteric, sponge/matrix implants, disk analysis system (DAS), and zebrafish.

The most commonly used matrix for maintaining cell growth in model generation is the soluble basement membrane preparation extracted from EHS mouse tumors, known as matrix gel, to ensure the success of angiogenesis or plug assays. Arcegel Matrix Gel is free of LDEV (lactic dehydrogenase elevating virus), has an ultra-low endotoxin content, and has undergone testing to guarantee absence of mycoplasma contamination, including different types of matrix gel such as basic concentration, high concentration, and low growth factor concentration.

 

Application directions

 

Product features

High Safety: Free of LDEV (Lactic Dehydrogenase Elevating Virus);

Diverse Concentrations: Concentration ranges between 8~20 mg/mL;

Good Batch Stability: Strict production quality inspection process ensures stable performance between batches;

Low Endotoxin: Endotoxin content <8 EU/mL;

Contaminant Detection: Tested negative for mycoplasma, bacteria, and fungal residues;

High Yield: Production exceeds 50L/month;

Excellent Compatibility: Compatible with any type of cell culture medium.

 

Matrix Gel Plug Assay

Experimental Procedure

1. Place BALB/c nude mice aged 3-7 weeks in a laminar flow barrier system for housing.

2. Remove Arcegel Matrix Gel from the -20°C freezer and allow it to thaw at 4°C for 12 hours until it becomes liquid.

3. Divide the mice into experimental groups: control group, VEGFA group, heparin sodium group, and VEGFA+heparin sodium group.

4. For the control group, inject 0.5 mL of high-concentration Arcegel Matrix Gel subcutaneously into the nude mice. For the VEGFA and heparin sodium groups, inject 0.5 mL of Matrix Gel containing VEGFA (20 μg/L) or heparin sodium (50 U/mL) subcutaneously into the nude mice, respectively. For the VEGFA+heparin sodium group, inject 0.5 mL of Matrix Gel containing a mixture of VEGFA (20 μg/L) and heparin sodium (50 U/mL) subcutaneously into the nude mice. The subcutaneous injection site should be near the midline of the mouse abdomen.

5. After 1 week, euthanize the nude mice and remove the matrix gel plugs. Measure hemoglobin concentration strictly according to the Drabkin reagent method.

Note: Preparation of Drabkin reagent: Dissolve 1.0g of sodium bicarbonate, 0.05g of potassium hydrogen phosphate, and 0.2g of ferric chloride in distilled water to a total volume of 1,000 mL. Store at 4°C.

 

Experimental Results

Figure: Results of BALB/c nude mice cultured for 7 days

 

 FAQ

What considerations should be taken into account during experimental procedures?

1. The high-concentration matrix gel tends to solidify easily. Pre-cool the matrix gel and injection needles on ice before inoculation.

2. Subcutaneous injection volume in nude mice is relatively large. Ensure proper needle depth to prevent leakage.

3. Maintain normal feeding and observe the injection site of the matrix gel. Stability can be observed for 1-2 weeks.

 

Related Products 

Product Type	Product Name	Catalog Number	Specification
Basic Concentration	Arcegel Matrix LDEV-Free	C231001	5/10 mL
	Arcegel Matrix Phenol Red-Free, LDEV-Free	C231002	5/10 mL
Low Growth Factor	Arcegel Matrix GFR, LDEV-Free Matrigel	C231003	5/10 mL
	Arcegel Matrix GFR, Phenol Red-Free, LDEV-Free	C231004	5/10 mL
High Concentration	Arcegel Matrix High Concentration, LDEV-Free	C231005	5/10 mL
	Arcegel Matrix High Concentration, Phenol Red-Free, LDEV-Free	C231006	5/10 mL
	Arcegel Matrix High Concentration, GFR, LDEV-Free	C231007	5/10 mL
Stem cell-specific	Arcegel Matrix hESC-Qualified, LDEV-Free	C231008	5/10 mL
Organoid-specific	Arcegel Matrix for Organoid culture, Phenol Red-Free, LDEV-Free	C231009	5/10 mL

 

Product Name	Catalog Number	Specifications
Intestinal Organoid Growth Medium (Mouse)	C231105	l00/500mL
Intestinal Cancer Organoid Growth Medium (Human)	C231106	l00/500mL
Gastric Cancer Organoid Growth Medium (Human)	C231107	l00/500mL
Liver Cancer Organoid Growth Medium (Human)	C231108	l00/500mL
Breast Cancer Organoid Growth Medium (Human)	C231109	l00/500mL
Lung Cancer Organoid Growth Medium (Human)	C231110	100/500mL
Esophageal Cancer Organoid Growth Medium (Human)	C231111	l00/500mL
Ovarian cancer Organoid Growth Medium (Human)	C231112	l00/500mL
Pancreatic cancer Organoid Growth Medium (Human)	C231113	l00/500mL